治愈性与维持性重复经颅磁刺激治疗难治性单相抑郁的成本-效用分析:随机对照试验方案
本研究为法国多中心、前瞻性、随机、双盲、三平行臂卫生经济学试验,计划纳入318例当前难治性单相抑郁患者。比较系统维持性低频rTMS、情绪恶化时追加rTMS疗程与安慰剂组(含假维持及追加)相比单独TAU的成本-效用,主要终点为12个月增量成本效果比(ICER,成本/QALY,EQ-5D测量)。
要点
- 系统维持或按需追加rTMS联合TAU与TAU单独比较成本-效用。
- 主要终点为12个月ICER(成本/QALY,EQ-5D测量)。
- 次要终点包括24个月ICER、预算影响及预后因素等。
核心结论
- 若rTMS能显著降低抑郁相关成本并带来良好长期预后(持续应答和缓解)及耐受性,则可视为难治性单相抑郁的有效治疗手段。
研究设计与样本
- 法国多中心、前瞻性、随机、双盲、三平行臂卫生经济学试验,计划纳入318例当前难治性单相抑郁患者。
- 干预为右侧背外侧前额叶低频rTMS辅助治疗及维持治疗,对照为单独TAU。
- A臂为应答者接受系统维持性rTMS;B臂为应答者情绪恶化时追加新rTMS疗程;C臂为安慰剂组(应答者分假系统维持和情绪恶化时追加rTMS两个亚组)。
主要发现
- 原文为研究方案,未报告研究结果。
关键数值与推荐
- 主要终点为12个月ICER(成本/QALY,QALY由Euroqol五维问卷测量),比较A臂或B臂 versus C臂。
- 次要终点包括24个月ICER、12和24个月成本-效用比分析、5年预算影响分析及rTMS预后因素。
- A臂或B臂与C臂比较的指标包括应答率、缓解率、无病生存率、临床演变、耐受性、依从性、治疗调整、住院、自杀尝试、停工、婚姻/职业状态及12和24个月生活质量。
临床怎么用
- 研究旨在评估rTMS的成本-效用及其随时间的经济影响,为难治性单相抑郁治疗决策提供卫生经济学依据。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Depression is a debilitating and costly disease for our society, especially in the case of treatment-resistant depression (TRD). Repetitive transcranial magnetic stimulation (rTMS) is an effective adjuvant therapy in treatment-resistant unipolar and non-psychotic depression. It can be applied according to two therapeutic strategies after an initial rTMS cure: a further rTMS cure can be performed at the first sign of relapse or recurrence, or systematic maintenance rTMS (M-rTMS) can be proposed. TMS adjuvant to treatment as usual (TAU) could improve long-term prognosis. However, no controlled study has yet compared the cost-effectiveness of these two additional rTMS therapeutic strategies versus TAU alone. METHODS/DESIGN: This paper focuses on the design of a health-economic, prospective, randomized, double-blind, multicenter study with three parallel arms carried out in France. This study assesses the cost-effectiveness of the adjunctive and maintenance low frequency rTMS on the right dorsolateral prefrontal cortex versus TAU alone. A total of 318 patients suffering from a current TRD will be enrolled. The primary endpoint is to investigate the incremental cost-effectiveness ratio (ICER) (ratio costs / quality-adjusted life-years [QALY] measured by the Euroqol Five Dimension Questionnaire) over 12 months in a population of patients assigned to one of three arms: systematic M-rTMS for responders (arm A); additional new rTMS cure in case of mood deterioration among responders (arm B); and a placebo arm (arm C) in which responders are allocated in two subgroups: sham systematic M-rTMS and supplementary rTMS course in case of mood deterioration. ICER and QALYs will be compared between arm A or B versus arm C. The secondary endpoints in each three arms will be: ICER at 24 months; the cost-utility ratio analysis at 12 and 24 months; 5-year budget impact analysis; and prognosis factors of rTMS. The following criteria will be compared between arm A or B and arm C: rates of responders; remission and disease-free survival; clinical evolution; tolerance; observance; treatment modifications; hospitalization; suicide attempts; work stoppage; marital / professional statues; and quality of life at 12 and 24 months. DISCUSSION: The purpose of our study is to check the cost-effectiveness of rTMS and we will discuss its economic impact over time. In the case of significant decrease in the depression costs and expenditures associated with a good long-term prognosis (sustained response and remission) and tolerance, rTMS could be considered as an efficient treatment within the armamentarium for resistant unipolar depression. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03701724. Registered on 10 October 2018. Protocol Amendment Version 2.0 accepted on 29 June 2019.
引用
- Bulteau S, Laurin A, Volteau C, et al. Cost-utility analysis of curative and maintenance repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant unipolar depression: a randomized controlled trial protocol. Trials. 2020. PMID: 32248820. doi:10.1186/s13063-020-04255-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。